Table 1.
Characteristics of the included indications between domestic and imported drugs.
| Characteristic | Domestic drugs, N (%) | Imported drugs, N (%) | P value |
|---|---|---|---|
| Included indications | 21 | 21 | NA |
| Cancer type | |||
| Non–small-cell lung cancer | 8 (38) | 9 (43) | 0.94 |
| Hepatocellular carcinoma | 5 (23) | 2 (10) | |
| Breast cancer | 3 (14) | 4 (19) | |
| Ovarian | 2 (10) | 2 (10) | |
| Colorectal | 1 (5) | 1 (5) | |
| Melanoma | 1 (5) | 1 (5) | |
| Prostate cancer | 1 (5) | 2 (10) | |
| Approval date | |||
| 2010–2015 | 1 (5) | 3 (14) | 0.61 |
| 2016–2022 | 20 (95) | 18 (86) | |
| 2021 NRDL | |||
| Included | 18 (86) | 15 (71) | 0.45 |
| Not included | 3 (14) | 6 (29) | |
| Approval types | |||
| Conditional approval | 10 (48) | 5 (24) | 0.20 |
| Regular approval | 11 (52) | 16 (76) | |
| Line of therapy | |||
| Adjuvant therapy | 0 (0) | 2 (10) | 0.39 |
| First-line advanced or metastatic | 9 (43) | 9 (43) | |
| Second-line advanced or metastatic | 9 (43) | 9 (43) | |
| Third- or- later-line advanced or metastatic | 3 (14) | 1 (5) |
NRDL, National Reimbursement Drug List; NA, not available.